ISRIB A15: A Complete Guide to the Compound, Dosing, and What to Expect

Most people find ISRIB A15 after exhausting everything else. Racetams that did nothing. Modafinil that worked for six months then stopped. Adaptogens that were indistinguishable from placebo. And then someone on a forum mentions ISRIB, and it sounds different — not in a hype way, but in a mechanistic way that actually holds up when you read the papers.

This guide is for people who are past the "is this real?" stage and want to understand what A15 actually is, how it works, and how to use it without making obvious mistakes.

What ISRIB A15 actually is

A15 is a structural analog of ISRIB — the original compound discovered at UCSF in 2013 by Peter Walter's lab. The original ISRIB had one practical problem: poor oral bioavailability and water solubility. You could get it to work in mice via injection, but oral dosing in humans was unreliable.

A15 addresses this. The modification — replacing chlorophenoxy groups with dichlorophenoxy groups — changes how the molecule is absorbed. The binding target is the same: eIF2B, the regulatory complex that controls protein synthesis in the ISR pathway. The potency is higher. The oral profile is better. For oral use, A15 in powder form can be weighed and taken directly, or encapsulated.

The mechanism, briefly

The Integrated Stress Response is a cellular pathway that pauses protein synthesis when cells are under stress. Short-term, this is protective. Long-term — under chronic stress, aging, or injury — the ISR becomes chronically activated, and the pause becomes a drag on normal function.

Memory formation requires new protein synthesis in neurons. An overactive ISR suppresses this. ISRIB targets eIF2B and stabilizes its active conformation, allowing protein synthesis to continue even when stress signals are present. You're not adding stimulant pressure to the brain — you're removing a molecular brake.

The significance of that 2013 finding is easy to miss. It wasn't just "ISRIB helps sick brains" — it was "ISRIB makes normal brains measurably better at memory tasks." That's a different and more interesting result.

Who tends to respond most clearly

Not everyone notices A15 in the same way. The pattern in consistent reports is that people with some form of accumulated cognitive suppression — stress, burnout, prolonged high-load periods — tend to report the clearest effects. People with essentially intact baseline cognition who are looking for a boost sometimes report milder or subtler effects.

This makes mechanistic sense. If your ISR is chronically elevated — as it tends to be after sustained stress or in aging — then removing that elevation has a larger effect than it would in someone whose ISR activity is already low.

The memory effect tends to be what people notice first. Not speed or energy — retrieval. Words come back. Concepts stick. The feeling people describe is less "on something" and more "back to normal," which is exactly what the mechanism predicts.

Dosing

This is where most people make their first mistake: starting too high.

A15 is potent. More potent than original ISRIB at equivalent doses. The reports of negative first experiences — fatigue, headaches, feeling "off" for a day — almost universally come from people who started at 10-15mg without any prior exposure.

A few things worth knowing about dosing that don't fit neatly in a table:

Timing doesn't matter much. Some people prefer morning, some evening. There's no strong evidence either way. A15 isn't stimulating, so it won't disrupt sleep. If you're sensitive, morning is probably sensible by default.

Food or no food. Most people report no difference. A small minority report mild nausea on an empty stomach at higher doses. Eat something first if you're in that camp.

Frequency is less than you'd think. The eIF2B stabilization effect appears to persist well beyond the compound's half-life. Daily dosing isn't necessary and may not add benefit. Every 2-3 days is the most commonly reported protocol. Some people use it weekly or in short cycles.

The first few days are not representative. A15's effects build. Day one is often unremarkable. Most people who report clear effects are reporting them from day 2-4. If you try it once, feel nothing, and conclude it doesn't work — you've probably not given it enough time.

What to expect, honestly

The effects most people report fall into a few categories. I'll describe them in the order they tend to appear.

Days 1-2: Often nothing notable, or a mild sense of something slightly different that's hard to pin down. Some people report mild fatigue on day one, especially at higher doses — this seems to be a transient effect as the brain adjusts to increased protein synthesis demand. Eat adequately.

Days 2-4: This is when most people notice something. Memory retrieval is the most consistent early effect — the ease of recalling things you know, fluency in conversation, less searching for words. Task engagement often changes before cognitive output does: things that felt effortful start feeling less so.

Week 2+: People who respond well often report that sustained use brings effects that weren't obvious in the first few days. Focus during complex tasks. Reduced cognitive fatigue at end of day. The "fog" that they'd normalized as baseline is noticeably absent.

I want to be honest about the variability here. Not everyone responds the same way. The Reddit reports and LongeCity logs cover a range from "completely changed my cognition" to "felt nothing at all." The non-responders are real. If you've tried 2-3 cycles at adequate doses and noticed nothing, A15 may simply not be the right tool for you — and that's information, not a failure.

The objections people have

Is it safe?

The honest answer: we don't have long-term human safety data. What we have is extensive animal safety data showing no toxicity at effective doses, and several years of biohacker self-reports with no serious adverse events documented.

Peter Walter — the compound's co-inventor — has described ISRIB as "totally benign" in their hands. That's a meaningful statement from the person who has studied this molecule longer than anyone. It's not a guarantee for humans at every possible dose and duration, but it's not nothing either.

The absence of dependence risk is probably the most important safety characteristic. A15's mechanism doesn't involve dopaminergic pathways that create compulsive use patterns. People don't report craving it or feeling withdrawal when they stop.

Is it legal?

A15 is sold as a research compound in most jurisdictions. It's not a controlled substance. The legal status is similar to other grey-market research chemicals — not explicitly approved for human use, not prohibited. This is a category you need to assess yourself based on your jurisdiction and risk tolerance.

How do I know it's not placebo?

I don't have a satisfying answer here. The honest position is: the effects described in user reports are unusually consistent and specific in ways that don't fit typical placebo patterns — particularly the memory retrieval effect, which is hard to fake to yourself. But without blinded trials in humans, you can't rule out placebo definitively.

What I can say: the animal data is not placebo. Mice don't have expectation effects. The consistency of the mechanism across species is one reason to take the human reports more seriously than you'd take reports for compounds with no animal backing.

What if I've already tried everything?

This is actually the population A15 seems to work best for. People who have tried racetams, modafinil, peptides, and various stacks — and found them either ineffective or not addressing the specific thing that feels wrong — are often the ones who report the clearest A15 effects.

The reason is probably mechanistic. A15 targets a pathway that other nootropics don't touch. If your cognitive issues are downstream of chronic ISR activation, then compounds that work on acetylcholine or dopamine are addressing the wrong upstream cause.

Storage and handling

Store in fridge at 2-6 degrees, away from light. The compound is stable but there's no reason to be careless — degraded material won't do anything useful, and A15 is expensive enough that wasting it to poor storage conditions is just unnecessary.

For powder dosing: a milligram-accurate scale is non-negotiable. A15 is active in the 5-20mg range. A kitchen scale with gram precision is useless here. The AWS Gemini series or similar jeweler's scales are adequate. Capsule filling is an alternative that removes the per-dose weighing requirement.

A15 dissolves in DMSO if you need a liquid solution. I've found this less convenient than powder for oral use, but some people prefer it for more precise volumetric dosing.

The research context

I want to end here because it matters. A15 exists in a specific moment in the research timeline — after enough animal work to establish a compelling mechanistic story, but before human trials have been completed. This is not a compound with 20 years of human safety data like modafinil. It's also not a compound with zero scientific backing like most nootropic supplements.

Calico — Google/Alphabet's longevity arm — is running ISRIB trials in ALS patients as of 2024. That's original ISRIB, not A15, and it's a disease population. But the fact that a well-resourced biotech chose ISRIB as a candidate says something about the scientific credibility of the underlying mechanism.

The biohacker community has been self-experimenting with A15 for a few years now. The reports are more consistent than most research chemicals generate. The mechanism is well-characterized. The animal safety data is genuinely reassuring.

Whether that's enough for you to try it is a decision you have to make yourself. I synthesized A15 because I found the data compelling enough to take seriously. I continue to find it compelling. I also continue to acknowledge that we're waiting for human trials to confirm what the animal literature suggests.

That uncertainty is real. It's also, at this point in the history of this compound, unavoidable.